[1] Lacheta J.Uterine adenomyosis: pathogenesis,diagnositics,symptomatology and treatment.Ceska Gynekol.2019 Spring;84(3):240-246.
[2] Buggio L, Monti E, Gattei U, Dridi D, Vercellini P. Adenomyosis: fertility and obstetric outcome. A comprehensive literature review. Minerva Ginecol. 2018 Jun;70(3):295-302.
[3] Naftalin J, Hoo W, Nunes N, Holland T, Mavrelos D, Jurkovic D. Association between ultrasound features of adenomyosis and severity of menstrual pain. Ultrasound Obstet Gynecol. 2016 Jun;47(6):779-83.
[4] Vannuccini S, Luisi S, Tosti C, Sorbi F, Petraglia F. Role of medical therapy in the management of uterine adenomyosis. Fertil Steril. 2018 Mar;109(3):398-405.
[5] Oliveira MAP, Crispi CP Jr, Brollo LC, Crispi CP, De Wilde RL. Surgery in adenomyosis. Arch Gynecol Obstet. 2018 Mar;297(3):581-589.
[6] Dueholm M. Minimally invasive treatment of adenomyosis. Best Pract Res Clin Obstet Gynaecol. 2018 Aug;51:119-137.
[7] Zhang L, Rao F, Setzen R. High intensity focused ultrasound for the treatment of adenomyosis: selection criteria, efficacy, safety and fertility. Acta Obstet Gynecol Scand. 2017 Jun;96(6):707-714.
[8] Yang X, Zhang X, Lin B, Feng X, Aili A. Combined therapeutic effects of HIFU, GnRH-a and LNG-IUS for the treatment of severe adenomyosis. Int J Hyperthermia. 2019;36(1):486-492.
[9]Gong C, Yang B, Shi Y, Liu Z, Wan L, Zhang H, Jiang D, Zhang L. Factors influencing the ablative efficiency of high intensity focused ultrasound (HIFU) treatment for adenomyosis: A retrospective study. Int J Hyperthermia. 2016 Aug;32(5):496-503.
[10] Liu xing hui,Zhang li,Zhang jing.Interpretation of Guideline on the Prophylaxis and Treatment of Postpartum(2009 and 2014).Chin J Obstet Gynecol Pediatr(Electron Ed),August 2015,11(4):433-447.
[11] Deneux-Tharaux C, Sentilhes L, Maillard F, Closset E, Vardon D, Lepercq J, Goffinet F. Effect of routine controlled cord traction as part of the active management of the third stage of labour on postpartum haemorrhage: multicentre randomised controlled trial (TRACOR). BMJ. 2013 Mar 28;346:f1541.
[12] Leduc D, Senikas V, Lalonde AB; CLINICAL PRACTICE OBSTETRICS COMMITTEE. Active management of the third stage of labour: prevention and treatment of postpartum hemorrhage. J Obstet Gynaecol Can. 2009 Oct;31(10):980-993.
[13] Atashkhoei S, Fakhari S, Pourfathi H, Bilehjani E, Garabaghi PM, Asiaei A. Effect of oxytocin infusion on reducing the blood loss during abdominal myomectomy: a double-blind randomised controlled trial. BJOG. 2017 Jan;124(2):292-298.
[14] Lozinski T, Filipowska J, Krol P, Kubaty A, Wegrzyn P. Oxytocin Administration in High-Intensity Focused Ultrasound Treatment of Myomata. Biomed Res Int. 2018 Jul 2;2018:7518026.
[15] Yu SC, Cheung EC, Leung VY, Fung LW. Oxytocin-Augmented and Non-Sedating High-Intensity-Focused Ultrasound (HIFU) for Uterine Fibroids Showed Promising Outcome As Compared To HIFU Alone or Uterine Artery Embolization. Ultrasound Med Biol. 2019 Dec;45(12):3207-3213.
[16] Zhang X, Zou M, Zhang C, He J, Mao S, Wu Q, He M, Wang J, Zhang R, Zhang L. Effects of oxytocin on high intensity focused ultrasound (HIFU) ablation of adenomysis: a prospective study. Eur J Radiol. 2014 Sep;83(9):1607-11.
[17] Zhang X,He J,Mao SH,Wang J,Wu Q,Zhang RT,Zhang L.Dose-effect research on the effect of OT on high intensity focused ultrasound ablation of adenomysis. Laser J.2013 Oct;34(6):103-104.
[18] Van den Bosch T, Dueholm M, Leone FP, Valentin L, Rasmussen CK, Votino A, Van Schoubroeck D, Landolfo C, Installé AJ, Guerriero S, Exacoustos C, Gordts S, Benacerraf B, D'Hooghe T, De Moor B, Brölmann H, Goldstein S, Epstein E, Bourne T, Timmerman D. Terms, definitions and measurements to describe sonographic features of myometrium and uterine masses: a consensus opinion from the Morphological Uterus Sonographic Assessment (MUSA) group. Ultrasound Obstet Gynecol. 2015 Sep;46(3):284-98.
[19] Richter O, Wardelmann E, Dombrowski F, Schneider C, Kiel R, Wilhelm K, Schmolling J, Kupka M, van der Ven H, Krebs D. Extracorporeal perfusion of the human uterus as an experimental model in gynaecology and reproductive medicine. Hum Reprod. 2000 Jun;15(6):1235-40.
[20] Weston GC, Cann L, Rogers PA. Myometrial microvascular endothelial cells express OT receptor. BJOG. 2003;110(2):149-156.
[21] Samy A, Raslan AN, Talaat B, El Lithy A, El Sharkawy M, Sharaf MF, Hussein AH, Amin AH, Ibrahim AM, Elsherbiny WS, Soliman HH, Metwally AA. Perioperative nonhormonal pharmacological interventions for bleeding reduction during open and minimally invasive myomectomy: a systematic review and network meta-analysis. Fertil Steril. 2020 Jan;113(1):224-233.e6.
[22] Murata T, Narita K, Ichimaru T. Rat uterine oxytocin receptor and estrogen receptor α and β mRNA levels are regulated by estrogen through multiple estrogen receptors. J Reprod Dev. 2014 Mar 7;60(1):55-61.
[23] Bilgin Z, Kömürcü N. Comparison of the effects and side effects of misoprostol and OT in the postpartum period: A systematic review. Taiwan J Obstet Gynecol. 2019;58(6):748-756.
[24] Shrestha A, Dongol A, Chawla CD. Rectal misoprostol versus intramuscular OT for prevention of post partum hemorrhage. Kathmandu Univ Med J (KUMJ). 2011;9(33):8-12.
[25] Atukunda EC, Siedner MJ, Obua C, Mugyenyi GR, Twagirumukiza M, Agaba AG. Sublingual misoprostol versus intramuscular oxytocin for prevention of postpartum hemorrhage in Uganda: a double-blind randomized non-inferiority trial. PLoS Med. 2014 Nov 4;11(11):e1001752.